世界の尿素呼気検査市場の規模、シェア、トレンド分析レポート – 業界の概要と2031年までの予測

尿素呼気検査市場分析

尿素呼気検査市場は、胃潰瘍や胃がんと関連のある細菌であるヘリコバクター・ピロリ（H. ピロリ）の非侵襲的検出における役割により、著しい成長を遂げています。検査の簡便性、正確性、および侵襲的処置を必要とせずに迅速な結果を提供できることから、病院、研究所、専門クリニックでの採用が増加しています。市場における最近の技術革新には、赤外線分光法や質量分析法などのポータブル検査機器の進歩があり、検査の感度と使いやすさが向上しています。胃腸障害の有病率の増加とH. ピロリ感染に関する認識の高まりが、市場の需要を刺激しています。ポイントオブケア検査（POCT）と研究所ベースの検査オプションの採用により、市場の範囲がさらに広がります。この分析は、技術が進化し続けるにつれて、尿素呼気検査市場は、特に胃障害の発生率が高く、医療インフラが改善されている地域で着実に拡大することを示しています。

尿素呼気検査市場規模

世界の尿素呼気検査市場規模は、2023年に1億2,321万米ドルと評価され、2024年から2031年の予測期間中に5.50%のCAGRで成長し、2031年には1億8,909万米ドルに達すると予測されています。市場価値、成長率、セグメンテーション、地理的範囲、主要プレーヤーなどの市場シナリオに関する洞察に加えて、Data Bridge Market Researchがまとめた市場レポートには、詳細な専門家分析、患者の疫学、パイプライン分析、価格分析、規制枠組みも含まれています。

尿素呼気検査市場の動向

「治療法の進歩」

The urea breath test market is growing rapidly due to its efficiency in diagnosing Helicobacter pylori infections, which are linked to gastric ulcers and stomach cancer. One significant trend in the market is the shift toward point-of-care testing (POCT), which allows faster, more accessible diagnostics in both hospital and outpatient settings. This trend is driven by the need for quicker results and convenience for patients and healthcare providers. Recent developments in portable urea breath test devices, including infrared and mass spectrometry-based analyzers, have further enhanced the test's accuracy and ease of use, making it more appealing to healthcare facilities worldwide. As gastrointestinal disorders and H. pylori infections continue to rise globally, the demand for non-invasive diagnostic tools is also increasing. This trend, combined with growing patient awareness and advancements in technology, is expected to boost the market in the coming years, particularly in regions with advanced healthcare infrastructure.

Report Scope and Urea Breath Test Market Segmentation    

Urea Breath Test Market Definition

The Urea Breath Test (UBT) is a non-invasive diagnostic tool primarily used to detect Helicobacter pylori (H. pylori) infection, a bacterium linked to conditions like peptic ulcers and stomach cancer. In this test, patients ingest a urea-containing substance labeled with either carbon-13 or carbon-14 isotopes. If H. pylori is present in the stomach, it breaks down the urea into carbon dioxide and ammonia. The isotopic carbon dioxide is then absorbed into the bloodstream and exhaled through the lungs, where it is measured via a breath sample. The UBT is highly accurate, quick, and safe, making it an ideal choice for diagnosing H. pylori infections and monitoring the effectiveness of treatment, without invasive procedures.

Urea Breath Test Market Dynamics

Drivers

• Increasing Prevalence of Helicobacter Pylori (H. pylori) Infections

Helicobacter pylori (H. pylori) infections are recognized as a significant contributor to peptic ulcers and gastric cancer, impacting millions worldwide. The increasing incidence of these gastrointestinal conditions has created a heightened demand for effective diagnostic tools. The Urea Breath Test (UBT) stands out as a non-invasive and highly efficient method for detecting H. pylori, making it a preferred choice for both patients and healthcare providers. In contrast to invasive procedures, the Urea Breath Test (UBT) provides rapid results without the discomfort typically linked to endoscopy. As awareness of H. pylori's role in serious gastrointestinal diseases grows, healthcare systems are more likely to incorporate UBT into their diagnostic protocols, further driving market expansion. Thus, the rising prevalence of H. pylori-related conditions significantly fuels the UBT market growth.

• Rising Awareness and Screening Programs

The growing awareness of Helicobacter pylori (H. pylori) and its associated health risks, including peptic ulcers and gastric cancer, is significantly impacting the Urea Breath Test (UBT) market. Health organizations and medical societies are actively conducting educational campaigns to inform both healthcare professionals and the public about the dangers posed by H. pylori infections. This increased awareness has led to a rise in screening initiatives, encouraging individuals to seek testing for early diagnosis and management of related conditions. As more people become informed about the link between H. pylori and serious gastrointestinal issues, the demand for non-invasive diagnostic tools like UBT is expected to rise. Consequently, this trend acts as a crucial driver for the growth of the UBT market.

Opportunities

• Increased Research and Development

Investment in research and development (R&D) is pivotal for advancing Urea Breath Test (UBT) technologies, presenting a significant market opportunity. Innovations focused on improving accuracy, speed, and user-friendliness can enhance the overall effectiveness of UBT, making it a more attractive option for healthcare providers. For instance, advancements in detection methods could lead to faster turnaround times for test results, allowing for prompt clinical decision-making. Additionally, the development of portable and point-of-care UBT devices can facilitate testing in diverse settings, from clinics to remote locations. As healthcare providers increasingly seek efficient and reliable diagnostic tools, the introduction of innovative UBT products could substantially expand its adoption, positioning R&D as a critical driver for growth in the UBT market. Thus, the ongoing emphasis on R&D represents a compelling market opportunity for stakeholders.

• Integration with Telehealth

The integration of Urea Breath Test (UBT) into telehealth platforms represents a transformative market opportunity in healthcare delivery, allowing for remote testing and consultations. This advancement enhances patient access to essential diagnostic services, particularly for individuals residing in rural or underserved areas where healthcare facilities may be limited. By utilizing telehealth technologies, patients can receive UBT conveniently from their homes, reducing barriers associated with travel and time constraints. This accessibility improves patient compliance with testing and facilitates timely diagnosis and treatment of Helicobacter pylori infections. Furthermore, the combination of remote monitoring and virtual consultations enables healthcare providers to follow up efficiently, ensuring comprehensive care. Overall, this shift towards telehealth significantly expands the reach and impact of UBT in the healthcare landscape, presenting a compelling market opportunity for stakeholders.

Restraints/Challenges

• Limited Awareness Among Healthcare Providers

Despite the increasing awareness among patients about the advantages of the Urea Breath Test (UBT) for diagnosing Helicobacter pylori infections, some healthcare providers remain unfamiliar with its benefits and may still favor traditional diagnostic methods. This can stem from a reliance on established practices, such as blood tests and endoscopic procedures, which have been historically used in clinical settings. Many providers may feel more comfortable recommending these conventional methods due to their familiarity and perceived reliability. As a result, even when patients express interest in undergoing UBT, healthcare providers might hesitate to endorse it, limiting its overall adoption in clinical practice. Bridging this knowledge gap is essential to address this market challenge and ensure that both patients and providers can fully leverage UBT's non-invasive advantages, ultimately improving patient outcomes in gastrointestinal health.

• Technological Barriers

The effectiveness of the Urea Breath Test (UBT) significantly depends on the availability of high-quality testing equipment and trained personnel who can administer the test correctly. Inadequate infrastructure, particularly in rural or resource-limited healthcare settings, can pose substantial challenges to the successful implementation of UBT. Facilities lacking modern diagnostic tools may not be equipped to perform UBT, thereby limiting patient access to this valuable diagnostic method. Additionally, the necessity for specialized training in UBT administration and interpretation of results cannot be overstated. Without properly trained personnel, the accuracy of the test may be compromised, leading to unreliable results and potential misdiagnoses. Consequently, these barriers can hinder the widespread adoption of UBT, representing a significant market restraint that prevents it from becoming a standard practice in gastrointestinal diagnostics.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Urea Breath Test Market Scope

The market is segmented on the basis of product type, test type, instrument, and application. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Product Type

• Urea Breath Test Kits
• Urea Breath Test Analyzer

Test Type

• Point-of-Care Tests (POCT)
• Laboratory-Based Test

Instrument

• Mass Spectrometer
• Infrared Spectrometer
• Laser Assisted Rationalizer

Application

• Hospitals
• Specialized Clinics
• Laboratories
• Others

Urea Breath Test Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, product type, test type, instrument, and application  as referenced above.

The countries covered in the market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America leads the urea breath test (UBT) market, driven by a rapidly growing geriatric population and the increasing adoption of advanced medical technologies. The region's healthcare infrastructure is well-equipped to support innovative diagnostic tools, enhancing the accessibility and efficiency of UBT. Additionally, rising awareness of gastrointestinal health issues among older adults further fuels demand for non-invasive testing methods. As a result, North America is poised to continue its dominance in the UBT market.

Asia-Pacific region is anticipated to experience the highest growth rate in the urea breath test (UBT) market from 2024 to 2031, driven by increasing health awareness among the population. As more individuals become informed about gastrointestinal health and the importance of early detection, the demand for non-invasive diagnostic tools like UBT is expected to rise. Additionally, the region's growing appetite for advanced medical technologies further supports this trend, as healthcare facilities seek to incorporate innovative solutions into their practices. Consequently, the Asia-Pacific market is well-positioned for significant expansion during the forecast period.

レポートの国別セクションでは、市場の現在および将来の動向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。下流および上流のバリュー チェーン分析、技術動向、ポーターの 5 つの力の分析、ケース スタディなどのデータ ポイントは、各国の市場シナリオを予測するために使用される指標の一部です。また、国別データの予測分析を提供する際には、グローバル ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、国内関税と貿易ルートの影響も考慮されます。  

尿素呼気検査の市場シェア

市場競争環境では、競合他社ごとの詳細が提供されます。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、世界的なプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などが含まれます。提供される上記のデータ ポイントは、市場に関連する会社の焦点にのみ関連しています。

尿素呼気検査市場で活動しているリーダー企業は次のとおりです。

• セルコングループ（英国）
• Kibion​​ GmbH (スウェーデン)
• アドバケアファーマ（米国）
• キズロン社（英国）
• メリディアン・バイオサイエンス社（米国）
• サーモフィッシャーサイエンティフィック株式会社（米国）
• バイオ・ラッド・ラボラトリーズ社（米国）
• パラディンファーマ社（カナダ）
• Eurofins Scientific (ルクセンブルク)
• 北京理辰力科技有限公司（中国）
• 深セン中和ヘッドウェイバイオサイエンス＆テクノロジー株式会社（中国）

尿素呼気検査市場の最新動向

• 2021年、大塚アメリカファーマシューティカル社は、北米のブレステック事業を、診断検査ソリューションおよびライフサイエンス原材料の大手グローバルプロバイダーであるメリディアンバイオサイエンス社に譲渡しました。この戦略的買収により、メリディアンは、特に消化器診断分野での市場での地位が向上することが期待されています。ブレステックポートフォリオを統合することで、メリディアンは提供を拡大し、この分野における既存の専門知識を活用することができます。この動きにより、同社は消化器診断ソリューション分野での成長と競争力の向上に向けて位置づけられます。

SKU-69174